Who is High-risk smoldering myeloma | Dr. S. Vincent Rajkumar

Daratumumab vs Active Monitoring in High-Risk Smoldering Multiple Myeloma: Aquila Study ResultsПодробнее

How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent RajkumarПодробнее

Smoldering Myeloma: The Epic DebateПодробнее

Advancing Myeloma Care: Dr. S. Vincent Rajkumar in with Dr. Sridevi Rajeeve | Oncology BrothersПодробнее

The importance of risk-stratifying treatment for multiple and smoldering myelomaПодробнее

Myeloma :2020 update- Dr. S. Vincent RajkumarПодробнее

IMWG Conference Series: Making Sense of Treatment ASH 2024Подробнее

Surinder K. Puri Memorial Lecture - S. Vincent Rajkumar, MDПодробнее

Risk Stratification of Plasma Cell DisordersПодробнее

Proposed 2019 treatment algorithms for MMПодробнее

How to define smoldering myeloma? RajkumarПодробнее

Accelerating Toward Curing Myeloma: New Data, New Agents, and Evolving Treatment ParadigmПодробнее

Winship Grand Rounds October 25, 2017: S. Vincent Rajkumar, MDПодробнее

Lenalidomide for smoldering myelomaПодробнее

Top 5 Multiple Myeloma Clinical Studies Presented at ASCO 2019Подробнее

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma StudiesПодробнее